13AFuse
$NEUP
What seems slightly odd is how Neuphoria shareholders on this bulletin board appear to have very little interest in Scancell, the company they are merging with.
Scancell have a Cancer Vaccine going in to Phase 3, with Phase 2 data points that are market leading.
Yesterday $SLS announced their Phase 3 cancer vaccine trial results out. It’s a niche cancer versus the melanoma that SCLP target, so they have a much smaller target market than SCLP.
Positive results tonight has seen their share price double to nearly $4BN
$MRNA is the best performing stock in the S & P 500, and by some distance this year, all because of their cancer vaccine results a couple of months ago. MRNA added approx $60 bn to their mcap from thise trial resuktss.
Scancell is a $5 bn+ company on good phase 3 data in my opinion, that’s 25-30x upside
4
